-
Mashup Score: 0Radiation-induced neuroinflammation: a potential protective role for poly(ADP-ribose) polymerase inhibitors? - PubMed - 1 year(s) ago
Radiotherapy (RT) plays a fundamental role in the treatment of glioblastoma (GBM). GBM are notoriously invasive and harbor a subpopulation of cells with stem-like features which exhibit upregulation of the DNA damage response (DDR) and are radioresistant. High radiation doses are therefore delivered …
Source: PubMedCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0AUAUniversity Podcast - 1 year(s) ago
The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org
Source: SoundCloudCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Hear from Maha Hussain from @LurieCancer and Ganesh Raj from @UTSWNews about #PARP inhibition for #prostatecancer and the patients who may benefit from PARP Inhibitor-based therapy https://t.co/nKEHRGaV8I via @AmerUrological #pcsm @NUFeinbergMed @NM_Urology https://t.co/fZNBGGR8gJ
-
-
Mashup Score: 1Scientific achievements of 2022 - 1 year(s) ago
We have picked 10 exciting scientific discoveries from the past academic year that brilliantly showcase the quality, breadth and strategic impact of our research.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At number 5 of #ICR10 - An ICR-led study (@IcrLordLab) revealed how #Cancer can resist #PARP inhibitors - a precision medicine used to treat thousands of patients worldwide - by removing the PARP proteins that get trapped onto their #DNA: https://t.co/ZTzP1Z1oxt https://t.co/dDp29DrdZJ
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase III #SOLO1 Trial Results: #Therapy with #PARP inhibitor, #olaparib, provided sustained benefit beyond the end of initial treatment for patients with newly diagnosed advanced #ovariancancer expressing the #BRCA mutation: https://t.co/GRz9ZjOnik @myESMO #ESMO22 https://t.co/ZodoMh3GIz
-
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase III #SOLO1 Trial Results: #Therapy with #PARP inhibitor, #olaparib, provided sustained benefit beyond the end of initial treatment for patients with newly diagnosed advanced #ovariancancer expressing the #BRCA mutation: https://t.co/GRz9ZjOnik @myESMO #ESMO22 https://t.co/6QaQK50tUx
-
-
Mashup Score: 1Clinical Commentary: Managing Adverse Events From PARP Inhibitors in Advanced Ovarian Cancer - 2 year(s) ago
At a live virtual event, Saketh Guntupalli, MD, discussed with participants the role of PARP inhibitors in the first-line setting for patients with advanced ovarian cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At a live virtual event, Saketh Guntupalli, MD, discussed with participants the role of #PARP inhibitors in the first-line setting for patients with advanced #ovariancancer. https://t.co/fVr7l4o0pR
-
-
Mashup Score: 0SGO 2022: GynOnc - Podcast - 2022 Gynecologic Conferences - 2 year(s) ago
Podcast episode with expert insights on new data from SGO 2022 in endometrial, ovarian, and cervical cancers, from Clinical Care Options (CCO)
Source: www.clinicaloptions.comCategories: Hem/Oncs, Latest HeadlinesTweet-
What were the highlights from #SGO2022? Podcast by @AngelesSecord & I. https://t.co/EamSB6EVDM #SGOMtg #ovariancancer #endometrialcancer #cervicalcancer @DrMatulonis @GOG @ZEJULA @LYNPARZAhcp #mirvetuximab @XPOVIO @KEYTRUDA @SGO_org #gyncsm #parp
-
-
Mashup Score: 4Our research impact: PARP inhibitors - 2 year(s) ago
To mark our outstanding success in REF2021, Alison Halliday spoke to several of our researchers here at the ICR who were instrumental in the development of PARP inhibitors, a type of targeted drug that’s been approved for use in breast, ovarian and prostate cancer.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our combined fundamental #Biology and clinical #Cancer research was instrumental in the development of #PARP inhibitors - a type of targeted drug that's been approved for use in #BreastCancer, #OvarianCancer and #ProstateCancer: https://t.co/TBl2ethqYN #REF2021
-
-
Mashup Score: 1
Cytarabine and other chain-terminating nucleoside analogs that damage replication forks in rapidly proliferating cells are a cornerstone of leukemia c…
Source: www.sciencedirect.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Chain-terminating nucleotides like #cytarabine damage replication forks & need #PARP1 for DNA repair. PARP1 is impaired in #leukemia cells with #DNMT3A mutations leading to #PARP inhibitor resistance. https://t.co/0PYQsdKIEE @gur_ola Article published in Experimental Hematology. https://t.co/Ayn5570wN3
-
-
Mashup Score: 0
Initial data from the phase 1/2a modular PETRA trial showed that the next-generation highly selective PARP1 inhibitor AZD5305 had comparable safety and promising clinical activity compared with first-generation PARP inhibitors.
Source: Urology TimesCategories: Latest Headlines, UrologyTweet-
Novel PARP inhibitor shows promise across solid tumors, including prostate cancer https://t.co/qmLe5MZHSU #urology #urologist #PARP #prostatecancer #pcsm
-
Very excited that our review article on the neuroprotective properties of #PARP inhibitors has made this list! Here’s the link to the article: https://t.co/f6lh6NJWY6 https://t.co/2pQCNIx31L